GCG and type 2 diabetes mellitus: In a study conducted by Tofé et al. [30] in patients with T2DM, treatment with GLP-1 RAs was efficient in reducing fasting glycaemia at 6 months (145 ± 51 mg/dL) and at 12 months (153 ± 53 mg/dL) as compared to the initial visit (177 ± 59 mg/dL), p < 0.0001.